Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Counterpoint: Vancomycin and Staphylococcus aureus - An antibiotic enters obsolescence 44th Annual Meeting of the Infectious-Diseases-Society-of-America Deresinski, S. UNIV CHICAGO PRESS. 2007: 1543–48

Abstract

The efficacy of vancomycin for the treatment of patients with infections due to Staphylococcus aureus is impaired by its poor tissue penetration and by its relatively weak antibacterial activity--an activity that is declining as S. aureus evolves. Neither dose escalation nor use of vancomycin in combination with other antibiotics that have antistaphylcoccal activity has been demonstrated to safely enhance its therapeutic efficacy. Although no clinical trials suggest superiority of vancomycin over any comparator, some have provided evidence of its inferiority. Strong consideration should be given to the use of alternative agents in the treatment of serious S. aureus infections.

View details for DOI 10.1086/518452

View details for Web of Science ID 000246658200004

View details for PubMedID 17516396